Summit Therapeutics (SMMT) Proxy filing summary

Executive summary

• Annual meeting scheduled for June 10, 2026, to be held virtually, with voting on key proposals including director elections, auditor ratification, executive compensation, and an amendment to the stock incentive plan.

• Board recommends voting in favor of all proposals, including the election of nine directors, ratification of PricewaterhouseCoopers LLP as auditor, approval of executive compensation, and an increase of 8,000,000 shares under the 2020 Stock Incentive Plan.

• Only stockholders of record as of April 15, 2026, are entitled to vote; multiple voting methods are available, including internet, phone, mail, and during the virtual meeting.

Voting matters and shareholder proposals

• Proposals include election of nine directors, auditor ratification, advisory vote on executive compensation, and amendment to increase shares under the stock incentive plan.

• Board unanimously recommends voting “FOR” all proposals.

• Shareholder proposals for the 2027 annual meeting must be submitted by December 18, 2026, to be considered for inclusion.

Board of directors and corporate governance

• Board consists of nine nominees, including a mix of executives and independent directors, with detailed biographies provided.

• Kenneth A. Clark serves as Lead Independent Director; five of nine directors are independent under Nasdaq rules.

• Board committees include Audit, Compensation, and Nominating and Corporate Governance, each with defined responsibilities and independent membership.

• Corporate governance guidelines, code of ethics, and insider trading policy are in place.